Tag: sodium-glucose transporter-2 inhibitors

HF Med Cornucopia Center Stage in Upcoming ESC Guideline: Preview

Today there are so many evidence-based drug therapies for heart failure (HF) with reduced ejection fraction (HFrEF) that physicians treating HF patients almost don’t know...

FDA Approves Finerenone for Slowing CKD in Type 2 Diabetes

The US Food and Drug Administration (FDA) approved finerenone (Kerendia), the first agent from a new class of nonsteroidal mineralocorticoid receptor antagonists (MRAs), on July...

Positive Top-Line Results for Empagliflozin in HFpEF

Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) significantly reduces the risk of cardiovascular death or hospitalization for heart failure...

Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes

Heart failure (HF) guidelines and practice have been quick to embrace the sodium-glucose cotransporter 2 (SGLT2) inhibitor drug class after DAPA-HF, EMPEROR-Reduced, and other trials...

Sotagliflozin’s HFpEF Benefit Confirmed by New Analyses

It’s now official: The investigational sodium-glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin is the first agent clearly shown in a prespecified analysis of randomized trials to improve...

Wearable Continuous Ketone Monitoring Appears Feasible

Continuous measurement of ketone levels with a wearable device is feasible, new research suggests. A small sensing device worn on the upper arm, similar to...

What’s the Best Second-Line Drug Class for Type 2 Diabetes?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes appear to confer greater cardiovascular benefit than glucagon-like peptide-1 (GLP-1) receptor agonists among older adults...

Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19

Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors during acute COVID-19 illness raises the risk for euglycemic diabetic ketoacidosis (euDKA), a new case series suggests. Five...

JACC Expert Consensus Decision Pathways for HF Treatment

A newly updated expert consensus from the American College of Cardiology (ACC) for management of heart failure with reduced ejection fraction (HFrEF) includes several new...

New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD

In a post-hoc analysis of the CREDENCE study, there were no safety signals when the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Janssen) was continued...

Empagliflozin Favorably Reshaped LVs in HFrEF Patients

Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of...

New ‘Myotropic’ Class Has Modest HFrEF Benefit

Omecamtiv mecarbil, a member of the novel myotropic drug class that improves cardiac performance, safely produced a significant but modest improvement in heart failure events...

Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups

Two different SGLT2 inhibitors produced broadly consistent beneficial effects across a spectrum of patients in two recent pivotal trials: one that enrolled patients with heart...

Dapagliflozin Halves Hyperkalemia in Some HF Patients

For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of...

Novel Drug Slows Progression of Diabetic Kidney Disease

For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined...

DAPA-CKD Resets eGFR Floor for Safe SGLT2 Inhibitor Use

The dramatically positive safety and efficacy results from the DAPA-CKD trial, which showed that treatment with the sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin significantly cut...

Ertugliflozin Benefit Falls Short of Other SGLT2 Inhibitors

Further analyses from the cardiovascular outcome trial of the sodium-glucose transporter 2 inhibitor ertugliflozin in patients with type 2 diabetes helped better define positive effects...

SGLT2 Inhibitor Benefits CKD Without Diabetes

Add patients with chronic kidney disease with or without diabetes to the growing list of people who get proven benefit from treatment with an SGLT2...

Empagliflozin’s HFrEF Benefit Solidifies Class Effects

The SGLT2 inhibitor drug class solidified its role as a major, new treatment for patients who have heart failure with reduced ejection fraction and no...

SGLT2 Inhibitors Now ‘Belong to Cardiologists and Nephrologists’

It’s passé to think of the sodium-glucose cotransporter 2 (SGLT2) inhibitor drugs as agents that primarily treat hyperglycemia because their major clinical role has rapidly...

Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF

The scope of sodium-glucose cotransporter 2 (SGLT2) inhibition’s clinical benefits in DAPA-HF may be greater than already appreciated, suggests a prespecified secondary analysis of the heart...

No Benefit of Diabetes Drug Ertugliflozin in CV Outcomes Trial VERTIS

The sodium-glucose transporter 2 (SGLT-2) inhibitor ertugliflozin broke ranks with the other drugs in its class and failed to produce statistically significant drops in the...